AAAAAA

   
Results: 1-9 |
Results: 9
Pharmacological approaches
Authors: Avila, PC Kishiyama, JL Adelman, DC
Citation: Pc. Avila et al., Pharmacological approaches, CL ALLER IM, 16, 2002, pp. 469-494
Photodynamic therapy with motexafin lutetium induces redox-sensitive apoptosis of vascular cells
Authors: Chen, ZP Woodburn, KW Shi, C Adelman, DC Rogers, C Simon, DI
Citation: Zp. Chen et al., Photodynamic therapy with motexafin lutetium induces redox-sensitive apoptosis of vascular cells, ART THROM V, 21(5), 2001, pp. 759-764
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
Authors: Gordon, MS Margolin, K Talpaz, M Sledge, GW Holmgren, E Benjamin, R Stalter, S Shak, S Adelman, DC
Citation: Ms. Gordon et al., Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer, J CL ONCOL, 19(3), 2001, pp. 843-850
Photoangioplasty recount: Clear punch or dimpled chad? Response
Authors: Rockson, SG Razavi, M Szuba, A Filardo, S Fitzgerald, P Cooke, JP Yousuf, S Kramer, P DeVault, AR Renschler, MF Adelman, DC
Citation: Sg. Rockson et al., Photoangioplasty recount: Clear punch or dimpled chad? Response, CIRCULATION, 104(11), 2001, pp. E55-E56
Photoangioplasty for human peripheral atherosclerosis - Results of a phaseI trial of photodynamic therapy with motexafin lutetium (Antrin)
Authors: Rockson, SG Kramer, P Razavi, M Szuba, A Filardo, S Fitzgerald, P Cooke, JP Yousuf, S DeVault, AR Renschler, MF Adelman, DC
Citation: Sg. Rockson et al., Photoangioplasty for human peripheral atherosclerosis - Results of a phaseI trial of photodynamic therapy with motexafin lutetium (Antrin), CIRCULATION, 102(19), 2000, pp. 2322-2324
Untitled
Authors: Shearer, WT Abramson, SL Adelman, DC Corn, B Cunningham-Rundles, C Kishiyama, JL Richmond, W Shames, RS Sperber, K Stiehm, ER Valacer, DJ
Citation: Wt. Shearer et al., Untitled, CLIN IMMUNO, 93(2), 1999, pp. 184-185
A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma
Authors: Kishiyama, JL Valacer, D Cunningham-Rundles, C Sperber, K Richmond, GW Abramson, S Glovsky, M Stiehm, R Stocks, J Rosenberg, L Shames, RS Corn, B Shearer, WT Bacot, B DiMaio, M Tonetta, S Adelman, DC
Citation: Jl. Kishiyama et al., A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma, CLIN IMMUNO, 91(2), 1999, pp. 126-133
Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects
Authors: Fahy, JV Cockcroft, DW Boulet, LP Wong, HH Deschesnes, F Davis, EE Ruppel, J Su, JQ Adelman, DC
Citation: Jv. Fahy et al., Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects, AM J R CRIT, 160(3), 1999, pp. 1023-1027
Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro andin vivo
Authors: Saini, SS MacGlashan, DW Sterbinsky, SA Togias, A Adelman, DC Lichtenstein, LM Bochner, BS
Citation: Ss. Saini et al., Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro andin vivo, J IMMUNOL, 162(9), 1999, pp. 5624-5630
Risultati: 1-9 |